In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial of the GLP-1-receptor agonist liraglutide, more biliary cancers were observed among those receiving active treatment vs placebo (six vs two events), with all but one event in the liraglutide group being cholangiocarcinomas [11]
doi: 10.3390/foods10061422 51
and Meng et al
Whether you want to boost your energy, lose weight, improve your overall wellness, or find [...] New Year, New You: Preparing for a Healthier 2025Stefani Hillin2025-05-21T11:34:20-06:00 Top 5 Health Trends for 2025: How Peak Medical Can Help You Stay Ahead Stefani Hillin2025-05-21T11:33:22-06:00 As we approach 2025, the focus on health and wellness continues to evolve, incorporating new technologies, treatments, and philosophies
M., Zheng, Y., & Tavassoli, T
BPC-157 showed no toxic dose in animal studies across a wide dosing range